ID   SCC-1-Erl-R
AC   CVCL_4V03
SY   Erl-R
DR   Wikidata; Q54952325
RX   PubMed=19190133;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (from parent cell line).
CC   Derived from site: In situ; Oral cavity, floor of mouth; UBERON=UBERON_0003679.
DI   NCIt; C4041; Floor of mouth squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7707 ! UM-SCC-1
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 19-12-24; Version: 14
//
RX   PubMed=19190133; DOI=10.1158/1078-0432.CCR-08-2068; PMCID=PMC2903727;
RA   Benavente S., Huang S.-M., Armstrong E.A., Chi A., Hsu K.-T.,
RA   Wheeler D.L., Harari P.M.;
RT   "Establishment and characterization of a model of acquired resistance
RT   to epidermal growth factor receptor targeting agents in human cancer
RT   cells.";
RL   Clin. Cancer Res. 15:1585-1592(2009).
//